Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Urinary Tract Infections, Urinary Retention, Satisfaction
Interventions: Fast Track foley removal; Other
Lead sponsor: The Christ Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: TP-05 (lotilaner oral capsules), Placebo; Drug
Lead sponsor: Tarsus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Delivery of Health Care, Genetic Testing, Humans, Pregnancy, Noninvasive Prenatal Testing, Informed Consent, Internet-Based Intervention, Self Efficacy, Pregnant People, Decision Making, Health Education, Patient Education as Topic/Method
Interventions: Mobile-based Educational Intervention; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: San Francisco, California • Jacksonville, Florida • Chapel Hill, North Carolina

Conditions: Pharmacokinetics, Epinephrine, Albuterol, Asthma, Anaphylaxis
Interventions: Epinephrine (0.125 mg/inhalation), Epinephrine Injection Auto-Injector (0.3mg/0.3mL), Albuterol Sulfate (0.09 mg/inhalation); Combination Product
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Aging Hands
Interventions: Transcutaneous electrical nerve stimulation (TENS), Familiarization; Behavioral
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 54 Years to 89 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Infection
Interventions: omiganan 1% gel, chlorhexidine 2% solution; Drug
Lead sponsor: Cadence Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Healthy
Interventions: BMS-986166, Placebo matching BMS-986166; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hookworm Infection, Hookworm Disease
Interventions: Na-GST-1/Alhydrogel®, CpG 10104; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Neck Pain
Interventions: Supine thoracic spine thrust manipulation, Seated thoracic spine thrust manipulation; Other
Lead sponsor: Northern Arizona University; Other
Eligibility: 20 Years to 50 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Flagstaff, Arizona

Conditions: Healthy
Interventions: K0706; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Acute Respiratory Failure
Interventions: Noninvasive positive pressure ventilation (NIPPV), Vapotherm; Device
Lead sponsor: Vapotherm, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Athens, Georgia • Florence, South Carolina • Chattanooga, Tennessee + 2 more

Conditions: Healthy
Interventions: Cilostazol Tablets 100 mg, Pletal® Tablets 100 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Posttraumatic Stress Disorder, Tinnitus
Interventions: resting-state functional MRI, Clinician Administered PTSD Scale for the DSM-5 (CAPS-5), Tympanometry, Tinnitus Assessment, Otoscopy, Pure tone air and bone-conduction, Speech testing, Loudness Discomfort, Quick Speech in Noise Test, Distortion-Product Otoacoustic Emissions (DPOAE); Diagnostic Test
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: Prasugrel ODT1 - Tablet, Prasugrel ODT2 - Tablet, Prasugrel ODT2 - Suspension; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Clarithromycin ER 500 mg tablets, BIAXIN® XL 500 mg tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Oxidative Stress, Dyslipidemias
Interventions: Octacosanol, Placebo; Dietary Supplement
Lead sponsor: Kosin University; Other
Eligibility: 17 Years to 19 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Dermatochalasis, Ptosis, Eyelid
Interventions: Randomized laterality of suture materials for closure (6-0 polypropylene monofilament suture vs fast absorbing gut suture on right eyelid); Procedure
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years to 89 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Postprandial Inflammation
Interventions: HFHC meal, HFHC MEAL plus Fiber; Other · Dietary Supplement
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Multiple Sclerosis
Interventions: Tolebrutinib, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Healthy Volunteer
Interventions: PX-866; Drug
Lead sponsor: Cascadian Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Blinded (placebo), Open Label (Avatrombopag tablets), Blinded (Avatrombopoag tablets); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 12
States / cities: Anaheim, California • Bakersfield, California • Manchester, Connecticut + 8 more

Conditions: Breast Cancer Prevention, Mammographic Density
Interventions: Ultrasound-guided core needle biopsy, Denosumab, Blood draw, Calcium, Vitamin D; Procedure · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 35 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Anesthesia
Interventions: Modified Time Principle Induction (MTPI) with rocuronium, RSI succinylcholine; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neurofibromatosis Type 1
Interventions: Selumetinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Rochester, Minnesota • Akron, Ohio

Search by objective public record fields.

Can Investigators Reduce Urinary Catheter Use and Lower Urinary Tract Infection Among Women Undergoing Benign Gynecologic Surgery?

A Pharmacokinetic Study of TP-05 in Healthy Subjects

Supporting Just-In-Time Consent for Prenatal Screening: The INFORM Study

Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals

Neural Substrates Underlying Adaptations in Manual Dexterity of Older Adults

Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Safety and Immunogenicity Study of Na-GST-1 With or Without CpG

A Comparison of Two Thoracic Manipulation Techniques to Improve Neck Pain

Bioavailability Study of K0706 in Healthy Subjects

High Flow Therapy for the Treatment of Respiratory Failure in the ED

Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mg

Neurobiological Similarities of Tinnitus and PTSD

A Study of Prasugrel in Healthy Participants

Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.

Effects of Octacosanol During Taekwondo Training

A Comparison of the Effect of Suture Material on Blepharoplasty Incision

Anti-inflammatory Effects of Fiber

Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants

Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers

Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

RANKL Inhibition and Breast Tissue Biomarkers

Comparison of Intubation Conditions During Rapid Sequence Induction Obtained With Modified Time Principal Induction With a Standard Intubation Dose of Rocuronium Versus Succinylcholine

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas